Additional Considerations Required While Assessing Suzhou Highfine Biotech's (SZSE:301393) Strong Earnings
Additional Considerations Required While Assessing Suzhou Highfine Biotech's (SZSE:301393) Strong Earnings
Investors were disappointed with Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) earnings, despite the strong profit numbers. We think that the market might be paying attention to some underlying factors that they find to be concerning.
投資者對蘇州中芯生物科技股份有限公司(SZSE:301393)的收益感到失望,儘管利潤數字強勁。我們認爲市場可能正在關注一些他們認爲令人擔憂的潛在因素。

The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
For anyone who wants to understand Suzhou Highfine Biotech's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥8.8m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If Suzhou Highfine Biotech doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
對於任何想了解蘇州中芯生物科技利潤超越法定數字的人來說,重要的是要注意,在過去十二個月中,法定利潤從880萬元的飛凡項目中獲得。我們不能否認,更高的利潤通常讓我們感到樂觀,但我們更希望利潤能夠持續。當我們對成千上萬家上市公司的數字進行分析時,我們發現,一年中來自飛凡項目的增長通常不會在下一年重複。這並不奇怪,鑑於其名稱。如果蘇州中芯生物科技看不到該貢獻再現,那麼其他條件相等,我們預期其今年的利潤將下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Suzhou Highfine Biotech.
注意:我們始終建議投資者檢查資產負債表的實力。點擊這裏查看我們對蘇州中芯生物科技的資產負債表分析。
Our Take On Suzhou Highfine Biotech's Profit Performance
我們對蘇州中芯生物科技的利潤表現看法
We'd posit that Suzhou Highfine Biotech's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Suzhou Highfine Biotech's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Suzhou Highfine Biotech's balance sheet by clicking here.
我們認爲蘇州海芬生物技術的法定收入並不完全反映其持續生產力,因爲涉及了一個較大的飛凡項目。因此,我們認爲蘇州海芬生物技術的法定利潤可能優於其潛在盈利能力。遺憾的是,過去十二個月其每股收益下降。本文的目標是評估我們能否依靠法定收入來體現公司的潛力,但還有更多因素需要考慮。投資者除了考慮收入外,還要考慮公司資產負債表的實力。我們進行了一些分析,您可以點擊這裏查看我們對蘇州海芬生物技術資產負債表的看法。
Today we've zoomed in on a single data point to better understand the nature of Suzhou Highfine Biotech's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天,我們聚焦於一個數據點,以更好地了解蘇州海芬生物技術利潤的性質。但如果您能集中注意力於細節,就總有更多發現。例如,許多人認爲高淨資產回報是有利的商業經濟指標,而另一些人喜歡「跟隨資金」並尋找內部人員正在購買的股票。因此,您可能希望查看這些擁有高淨資產回報的公司的免費收集,或者這些擁有高內部所有權股票的列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。